231 related articles for article (PubMed ID: 30062975)
1. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
[TBL] [Abstract][Full Text] [Related]
2. Gedunin abrogates aldose reductase, PI3K/Akt/mToR, and NF-κB signaling pathways to inhibit angiogenesis in a hamster model of oral carcinogenesis.
Kishore T KK; Ganugula R; Gade DR; Reddy GB; Nagini S
Tumour Biol; 2016 Feb; 37(2):2083-93. PubMed ID: 26342697
[TBL] [Abstract][Full Text] [Related]
3. Nimbolide, a Neem Limonoid, Inhibits Angiogenesis in Breast Cancer by Abrogating Aldose Reductase Mediated IGF-1/PI3K/Akt Signalling.
Nivetha R; Arvindh S; Baba AB; Gade DR; Gopal G; K C; Reddy KP; Reddy GB; Nagini S
Anticancer Agents Med Chem; 2022; 22(14):2619-2636. PubMed ID: 35125086
[TBL] [Abstract][Full Text] [Related]
4. Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer.
Sophia J; Kowshik J; Dwivedi A; Bhutia SK; Manavathi B; Mishra R; Nagini S
Cell Death Dis; 2018 Oct; 9(11):1087. PubMed ID: 30352996
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting the PI3K/Akt, NF-κB signalling pathways with syringic acid for attenuating the development of oral squamous cell carcinoma cells SCC131.
Velu P; Vijayalakshmi A; Vinothkumar V
J Pharm Pharmacol; 2020 Nov; 72(11):1595-1606. PubMed ID: 32790092
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury.
El Gamal H; Eid AH; Munusamy S
Biomed Res Int; 2017; 2017():5903105. PubMed ID: 28386557
[TBL] [Abstract][Full Text] [Related]
7. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
[TBL] [Abstract][Full Text] [Related]
8. Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF-κΒ/STAT3 signalling axis in oral squamous cell carcinoma models.
Kowshik J; Nivetha R; Ranjani S; Venkatesan P; Selvamuthukumar S; Veeravarmal V; Nagini S
IUBMB Life; 2019 Oct; 71(10):1595-1610. PubMed ID: 31251469
[TBL] [Abstract][Full Text] [Related]
9. Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3β in a hamster model of oral oncogenesis.
Sophia J; Kiran Kishore T K; Kowshik J; Mishra R; Nagini S
Sci Rep; 2016 Feb; 6():22192. PubMed ID: 26902162
[TBL] [Abstract][Full Text] [Related]
10. Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
Banala VT; Urandur S; Sharma S; Sharma M; Shukla RP; Marwaha D; Gautam S; Dwivedi M; Mishra PR
Biomater Sci; 2019 Jun; 7(7):2889-2906. PubMed ID: 31086900
[TBL] [Abstract][Full Text] [Related]
11. Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS.
Wang X; Yu F; Zheng WQ
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):294-303. PubMed ID: 31389594
[TBL] [Abstract][Full Text] [Related]
12. Gedunin inhibits pancreatic cancer by altering sonic hedgehog signaling pathway.
Subramani R; Gonzalez E; Nandy SB; Arumugam A; Camacho F; Medel J; Alabi D; Lakshmanaswamy R
Oncotarget; 2017 Feb; 8(7):10891-10904. PubMed ID: 26988754
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.
Ramana KV; Tammali R; Srivastava SK
Mol Cancer Ther; 2010 Apr; 9(4):813-24. PubMed ID: 20354121
[TBL] [Abstract][Full Text] [Related]
15. Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-κB and MAPK pathways.
Zeng KW; Li J; Dong X; Wang YH; Ma ZZ; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2013 Nov; 273(1):159-71. PubMed ID: 24021941
[TBL] [Abstract][Full Text] [Related]
16. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
[TBL] [Abstract][Full Text] [Related]
18. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
Elmazoglu Z; Prnova MS; Stefek M; Ceylan AF; Aschner M; Rangel-López E; Santamaria A; Karasu C
Neurotox Res; 2021 Jun; 39(3):588-597. PubMed ID: 33713301
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations.
Huang Z; Hong Q; Zhang X; Xiao W; Wang L; Cui S; Feng Z; Lv Y; Cai G; Chen X; Wu D
Cell Commun Signal; 2017 Jan; 15(1):3. PubMed ID: 28057038
[TBL] [Abstract][Full Text] [Related]
20. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
